Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–15 of 15 results
Advanced filters: Author: Hiddo J. Lambers Heerspink Clear advanced filters

  • The SONAR trial showed that the endothelin receptor antagonist atrasentan improves kidney outcomes in patients with type 2 diabetes and chronic kidney disease, though individual responses varied. Here the authors report exploratory analyses of the SONAR trial that identify urinary clusterin as a potential predictor of kidney disease progression and response atrasentan in type 2 diabetes.

    • Wenjun Ju
    • Viji Nair
    • Hiddo J. L. Heerspink
    ResearchOpen Access
    Nature Communications
    P: 1-16

  • In a meta-analysis of 48 randomized trials of chronic kidney disease progression, reduction in the 6-month urinary albumin:creatinine ratio was associated with lower hazard ratios of established kidney disease endpoints, supporting the use of albuminuria change as a surrogate endpoint in clinical trials for chronic kidney disease.

    • Hiddo J. L. Heerspink
    • Willem H. Collier
    • Lesley A. Inker
    Research
    Nature Medicine
    Volume: 32, P: 281-287

  • Results from the ROADMAP trial have highlighted the discrepancy between the renoprotective effects of olmesartan treatment in patients with type 2 diabetes mellitus, and the observed increase in cardiovascular deaths. Several explanations for these results need to be considered, which may influence future clinical practice.

    • Sara S. Roscioni
    • Hiddo J. Lambers Heerspink
    • Dick de Zeeuw
    News & Views
    Nature Reviews Nephrology
    Volume: 7, P: 427-428

  • Makani and colleagues report that dual blockade of the renin–angiotensin–aldosterone system is associated with harm despite previous studies showing that this approach decreases blood pressure and albuminuria. Do these results imply that we should abandon surrogate markers? Or should we become more creative in using them?

    • Hiddo J. Lambers Heerspink
    • Dick de Zeeuw
    News & Views
    Nature Reviews Endocrinology
    Volume: 9, P: 261-263

  • New data suggest that treatment with patiromer or sodium zirconium cyclosilicate for up to 8 weeks reduces plasma potassium levels in hyperkalaemic patients. If proven safe and effective for long-term use, these therapies might be administered together with intensive renin–angiotensin–aldosterone blockade to reduce adverse effects and renal and cardiovascular risk.

    • Sara S. Roscioni
    • Hiddo J. Lambers Heerspink
    News & Views
    Nature Reviews Nephrology
    Volume: 11, P: 205-206

  • In diabetic nephropathy, excessive activation of the renin–angiotensin–aldosterone system (RAAS) results in progressive renal damage. Here, the authors discuss the efficacy of RAAS blockade for the prevention of disease progression and the mechanisms of renal protection. They also highlight new strategies aimed at optimizing RAAS blockade and improving outcomes in patients with diabetic nephropathy.

    • Sara S. Roscioni
    • Hiddo J. Lambers Heerspink
    • Dick de Zeeuw
    Reviews
    Nature Reviews Nephrology
    Volume: 10, P: 77-87

  • Blockade of the renin-angiotensin-aldosterone system (RAAS) is a standard treatment for patients with chronic kidney disease (CKD). Intensive strategies with single-agent or dual-agent RAAS blockade have been used to reduce proteinuria and blood pressure in these patients. This Review discusses strategies for improving the long-term outcomes of patients with CKD treated with RAAS blockade, focusing on the effects of combined low-dietary sodium intake and RAAS-blockade on the risk of renal and cardiovascular outcomes.

    • Hiddo J. Lambers Heerspink
    • Martin H. de Borst
    • Gerjan J. Navis
    Reviews
    Nature Reviews Nephrology
    Volume: 9, P: 112-121

  • Mineralocorticoid-receptor antagonists (MRAs) effectively reduce blood pressure and albuminuria in patients with chronic kidney disease who experience aldosterone breakthrough. Use of MRAs is limited, however, by the occurrence of hyperkalaemia, which frequently develops in patients with impaired kidney function, and/or diabetes. This Review discusses potential approaches to identify patients who are particularly prone to developing hyperkalaemia with MRA therapy and describes currently available and promising strategies to prevent and control hyperkalaemia in patients with CKD.

    • Sara S. Roscioni
    • Dick de Zeeuw
    • Hiddo J. Lambers Heerspink
    Reviews
    Nature Reviews Nephrology
    Volume: 8, P: 691-699

  • In participants with obesity and chronic kidney disease without diabetes, once-weekly administration of semaglutide 2.4 mg led to a reduction in albuminuria, body weight and systolic blood pressure compared with placebo, with no changes to creatinine or cystatin-C estimated glomerular filtration rate or measured glomerular filtration rate during the 24-week follow-up period.

    • Ellen M. Apperloo
    • Jose L. Gorriz
    • Hiddo J. L. Heerspink
    Research
    Nature Medicine
    Volume: 31, P: 278-285

  • Clinical trials of sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists have shown beneficial effects of these agents on kidney outcomes in patients with type 2 diabetes mellitus. Two new cohort studies now demonstrate that these findings are generalizable to the broad range of patients seen in clinical practice.

    • Annemarie B. van der Aart-van der Beek
    • Hiddo J. L. Heerspink
    News & Views
    Nature Reviews Nephrology
    Volume: 16, P: 433-434

  • Endothelin-1 (ET-1) is a potent vasoactive peptide that is produced by various cell types of the kidney and regulates a variety of physiological processes. This Review describes the role of ET-1 in the kidney and in the development of chronic kidney disease, and the kidney-protective effects of endothelin-receptor antagonists in preclinical and clinical studies.

    • J. David Smeijer
    • Donald E. Kohan
    • Hiddo J. L. Heerspink
    Reviews
    Nature Reviews Nephrology
    Volume: 21, P: 175-188

  • Clinical trials have demonstrated sodium–glucose co-transporter 2 (SGLT2) inhibitors to be safe and effective drugs that improve kidney outcomes in patients with and without diabetes. SGLT2 inhibitors also improve heart failure outcomes for patients with preserved or reduced ejection fraction. This Review summarizes findings from clinical trials of SGLT2 inhibitors, focusing on the effects of these agents in patients with chronic kidney disease and heart failure, and describes how potential mechanisms of action may translate into clinical benefit.

    • Annemarie B. van der Aart-van der Beek
    • Rudolf A. de Boer
    • Hiddo J. L. Heerspink
    Reviews
    Nature Reviews Nephrology
    Volume: 18, P: 294-306